

# Clinical trials of Fluoxetine

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 obesity and overweight

Trial	Treatments	Patients	Trials design and methods
<b>Fluoxetine vs placebo</b>			
<a href="#">Breum , 1995</a> n=20/20 follow-up:	Fluoxetine, 60 mgfor 52 wk versus Placebo	aaaa	
<a href="#">Connolly , 1995</a> n=15/15 follow-up:	fluoxetine 60 mg daily versus placebo	obese elderly patients over 60 years of age with Type 2 diabetes	double-blind
<a href="#">Darga , 1991</a> n=23/22 follow-up: 52 weeks	fluoxetine versus placebo	obese subjects	
<a href="#">Goldstein , 1994</a> n=182/184 follow-up: 52-week	Fluoxetine, 60 mgfor 52 wk versus Placebo	obese outpatients	double-blind
<a href="#">Gray , 1992</a> n=24/24 follow-up: 24 weeks	Fluoxetine, 60 mg for 6 mo versus Placebo	obese, type 2 non-insulin dependent diabetics being treated with insulin	double blind
<a href="#">Marcus , 1990</a> n=23/22 follow-up:	Fluoxetine, 60 mgfor 52 wk versus Placebo	-	
<a href="#">Mendoza Espejo , 1995</a> n=0/30 follow-up:	Fluoxetine, 180 mgfor 6 mo versus Placebo	-	
<a href="#">Michelson 50wk , 1999</a> n=102/102 follow-up:	Fluoxetine, 20 mgfor 50 wk versus Placebo	-	
<a href="#">OKane , 1994</a> n=10/10 follow-up:	-	-	

More details and results :

- All mechanism for obesity and overweight in all type of patients at <http://www.trialresultscenter.org/go-Q265>

## References

### **Breum, 1995:**

Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. *Metabolism* 1995 Dec;44:1570-6 [[8786726](#)]

### **Connolly, 1995:**

Connolly VM, Gallagher A, Kesson CM A study of fluoxetine in obese elderly patients with type 2 diabetes. *Diabet Med* 1995 May;12:416-8 [[7648804](#)]

### **Darga, 1991:**

Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP Fluoxetine's effect on weight loss in obese subjects. *Am J Clin Nutr* 1991 Aug;54:321-5 [[1858696](#)]

### **Goldstein, 1994:**

Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR Fluoxetine: a randomized clinical trial in the treatment of obesity. *Int J Obes Relat Metab Disord* 1994 Mar;18:129-35 [[8186809](#)]

### **Gray, 1992:**

Gray DS, Fujioka K, Devine W, Bray GA Fluoxetine treatment of the obese diabetic. *Int J Obes Relat Metab Disord* 1992 Mar;16:193-8 [[1317828](#)]

### **Marcus, 1990:**

Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. *Am J Psychiatry* 1990 Jul;147:876-81 [[2192563](#)]

### **Mendoza Espejo, 1995:**

Mendoza Espejo R, Diaz Perez de Madrid J, Buitrago F [Effectiveness of serotonergic agonists in the treatment of obese patients] *Aten Primaria* 1995 Oct 15;16:364-6 [[7488690](#)]

### **Michelson 50wk, 1999:**

Michelson D, Amsterdam JD, Kim Y, Sundell K.nten Changes in weight during a one-year trial with fluoxetine [Abstract] 152nd Annual Meeting of

### **OKane, 1994:**

O'Kane M, Wiles PG, Wales JK Fluoxetine in the treatment of obese type 2 diabetic patients. *Diabet Med* 1994 Jan-Feb;11:105-10 [[8181239](#)]